Furthermore, mutant ErbB4 in melanoma cells is associated with increased cell growth and this growth is reduced when these cells are treated with the ErbB inhibitor lapatinib (75).Silencing endogenous ErbB4 in ErbB4 mutant-expressing melanoma cells leads to an arrest in AKT phosphorylation and cellular proliferation (75). This evidence concerns the gene AKT1 and melanoma.